Prognostic Value of Glucose Transporter 3 Expression in Hepatocellular Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Dec 31

PMID 31885715

Citations 15

Authors

Hengjun Gao

Yijie Hao

Xu Zhou

Hongguang Li

Fangfeng Liu

Huaqiang Zhu

Xie Song

Zheyu Niu

Qingqiang Ni

Min-Shan Chen

Jun Lu

Affiliations

Soon will be listed here.

Abstract

Determining an effective biomarker for predicting the prognosis of patients with hepatocellular carcinoma (HCC) may improve patient survival rates. The present study aimed to investigate the expression of glucose transporter 3 (GLUT-3) in HCC and to determine its predictive value for the survival of patients with HCC. Immunohistochemistry was used to detect GLUT-3 expression in HCC tissues of 275 and 140 patients with HCC from training and validation cohorts, respectively. The association between GLUT-3 expression and the clinicopathological characteristics of patients with HCC, and between GLUT-3 expression and patient survival rates were analyzed. The predictive value of GLUT-3 expression was confirmed using the validation cohort. The results demonstrated that the high GLUT-3 expression in HCC tissues was significantly associated with elevated α-fetoprotein level, large tumor size, poor histological differentiation and Tumor-Node-Metastasis stages III and IV (P<0.05). In addition, GLUT-3 high expression was also significantly associated with reduced overall survival of patients with HCC in the training and validation cohorts. In conclusion, the results from the present study suggested that GLUT-3 may be considered as a potential independent prognostic factor for predicting the survival of patients with HCC.

Citing Articles

Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma.

Wang K, Li X, Guo S, Chen J, Lv Y, Guo Z Front Oncol. 2025; 15:1545086.

PMID: 39980550 PMC: 11839411. DOI: 10.3389/fonc.2025.1545086.

Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.

Eghbali S, Heumann T Cancers (Basel). 2025; 17(2).

PMID: 39858016 PMC: 11764197. DOI: 10.3390/cancers17020236.

A narrative review: exploring viral-induced malignancies through the lens of dysregulated cellular metabolism and glucose transporters.

Shahpar A, Hamidi Sofiani V, Nezhad N, Charostad M, Ghaderi R, Farsiu N BMC Cancer. 2024; 24(1):1329.

PMID: 39472817 PMC: 11520837. DOI: 10.1186/s12885-024-13013-y.

SLC2A3 is a Potential Factor for Head and Neck Squamous Cancer Development through Tumor Microenvironment Alteration.

Jiang W, Xu S, Li P Curr Gene Ther. 2024; 25(2):157-177.

PMID: 38778609 PMC: 11774314. DOI: 10.2174/0115665232291300240509104344.

Predictive model using four ferroptosis-related genes accurately predicts gastric cancer prognosis.

Wang L, Gong W World J Gastrointest Oncol. 2024; 16(5):2018-2037.

PMID: 38764813 PMC: 11099433. DOI: 10.4251/wjgo.v16.i5.2018.

References

Rojas Ayala F, Rocha R, Carvalho K, Carvalho A, da Cunha I, Lourenco S . GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. Molecules. 2010; 15(4):2374-87. PMC: 6257354. DOI: 10.3390/molecules15042374. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G . Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006; 44(4):723-31. DOI: 10.1016/j.jhep.2005.12.015. View

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

Barron C, Bilan P, Tsakiridis T, Tsiani E . Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016; 65(2):124-39. DOI: 10.1016/j.metabol.2015.10.007. View

Conde V, Oliveira P, Nunes A, Rocha C, Ramalhosa E, Pereira J . The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Exp Cell Res. 2015; 335(1):91-8. DOI: 10.1016/j.yexcr.2015.04.007. View

Haber R, Weinstein S, OBoyle E, Morgello S . Tissue distribution of the human GLUT3 glucose transporter. Endocrinology. 1993; 132(6):2538-43. DOI: 10.1210/endo.132.6.8504756. View

Zhong Z, Wen Z, Darnell Jr J . Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994; 264(5155):95-8. DOI: 10.1126/science.8140422. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

10.

Lunt S, Vander Heiden M . Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011; 27:441-64. DOI: 10.1146/annurev-cellbio-092910-154237. View

11.

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

12.

Boado R, Black K, Pardridge W . Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res. 1994; 27(1):51-7. DOI: 10.1016/0169-328x(94)90183-x. View

13.

Starska K, Forma E, Jozwiak P, Brys M, Lewy-Trenda I, Brzezinska-Blaszczyk E . Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis. Tumour Biol. 2014; 36(4):2309-21. PMC: 4428538. DOI: 10.1007/s13277-014-2838-4. View

14.

Maratou E, Dimitriadis G, Kollias A, Boutati E, Lambadiari V, Mitrou P . Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 2007; 37(4):282-90. DOI: 10.1111/j.1365-2362.2007.01786.x. View

15.

Nault J, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G . A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013; 145(1):176-187. DOI: 10.1053/j.gastro.2013.03.051. View

16.

Fitzmaurice C, Akinyemiju T, Al Lami F, Alam T, Alizadeh-Navaei R, Allen C . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018; 4(11):1553-1568. PMC: 6248091. DOI: 10.1001/jamaoncol.2018.2706. View

17.

Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A . Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res. 2012; 18(3):721-8. PMC: 3342495. DOI: 10.1007/s12253-012-9500-5. View

18.

OROURKE J, Pugh C, Bartlett S, Ratcliffe P . Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem. 1996; 241(2):403-10. DOI: 10.1111/j.1432-1033.1996.00403.x. View

19.

Baumann M, Zamudio S, Illsley N . Hypoxic upregulation of glucose transporters in BeWo choriocarcinoma cells is mediated by hypoxia-inducible factor-1. Am J Physiol Cell Physiol. 2007; 293(1):C477-85. PMC: 4497554. DOI: 10.1152/ajpcell.00075.2007. View

20.

Chun Y, Kim S, Park J, Kim D, Han K, Chon C . Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011; 47(17):2568-75. DOI: 10.1016/j.ejca.2011.07.002. View